AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01427062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental
Description: Subjects in the experimental group were trained the speed and amplitude of anticipatory postural adjustment during fall-prone activities and postural response to perturbation during walking. Training was provided with preparatory cues, computerized machines and treadmill.
Study NCT01427062 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Subjects in control group were provided with strength training of leg muscles using machines and during functional activities.
Study NCT04007835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: anlotinib (12 mg orally daily for 14 days every 21 days cycle) combined with one of EGFR-TKIs
Study NCT01577173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEHD7945A
Description: 1100 mg iv every 2 weeks
Study NCT01577173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: 400 mg/m2 iv loading dose, followed by 250 mg/m2 weekly
Study NCT03675763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual treatment
Description: Craniosacral therapy protocol.
Study NCT02298517 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inspiratory load equipment
Description: Threshold and Power breathe
Study NCT01037374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative assessment form
Description: (based on the american society of anesthesiologists)components of the form include: neck measurements; neck mobility; mallampati; wilson's test; pre-existing conditions; and predictions of difficult mask ventilation, supraglottic airway, laryngoscopy, intubation, and surgical airway.
Study NCT02636764 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: exercises designed with the objective of strengthening the musculature: flexor and extensor of the knee; extensor, abductor, lateral rotator of the hip.
Study NCT02636764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercises designed with the objective of strengthening the musculature: flexor and extensor of the knee; extensor, abductor, lateral rotator of the hip.
Study NCT02636764 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: exercise
Description: exercises designed with the objective of strengthening the musculature: flexor and extensor of the knee; extensor, abductor, lateral rotator of the hip.
Study NCT02636764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: interferential current
Description: The basic principle of Interferential Therapy (IFT) is to utilise the significant physiological effects of low frequency (\<250pps) electrical stimulation of nerves without the associated painful and somewhat unpleasant side effects sometimes associated with low frequency stimulation
Study NCT02636764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: short-wave diathermy
Description: Is a modality that produces deep heating via conversion of electromagnetic energy to thermal energy
Study NCT02636764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: Laser treatment in which the energy output is low enough so that the temperature of the treated tissue does not rise above 98.6°F (36.5° C) or normal body temperature.
Study NCT02636764 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound therapy
Description: Ultrasound (US) is a form of mechanical energy, not electrical energy and therefore strictly speaking, not really electrotherapy at all but does fall into the Electro Physical Agents grouping.
Study NCT01284179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Hypnotherapy
Description: Each session contains the following elements: (1) trance induction consisting of narrowing the focus of attention and eye-closure, (2) trance deepening through imagery, guided dissociation from the here-and-now and graded suggestions of change in mental state, (3) vivid guided imagery that engages all the senses and implies improved health, well-being and a sense of strength and personal power, (4) therapeutic suggestions and imagery, both direct and indirect, for enhanced chest comfort, overall physical comfort and mental well-being and immunity to discomfort, that is suggested will last beyond termination of the session and become more noticeable and permanent over time, and (5) trance termination through direct suggestions and counting.
Study NCT01284179 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational
Description: Educational recordings regarding FCP and FGIDs.
Study NCT01325935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: DAPT using aspirin 81 mg/day (minimal dose) and clopidogrel 75 mg/day should be conducted for 3 months (+ 30 days) after stenting.
Study NCT01664039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% ophthalmic solution
Description: Ophthalmic solution without benzalkonium chloride (BAK), containing Polyquad® preservative
Study NCT01664039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost 0.01% ophthalmic solution
Description: Ophthalmic solution containing benzalkonium chloride (BAK)
Study NCT03117244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise for Foot Strengthening
Description: Stabilization exercises of the longitudinal arch of the foot
Study NCT03117244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise for Foot Strengthening and Electrostimulation
Description: Exercise for the Strengthening of the Foot associated with Electrostimulation
Study NCT00980941 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soup with or without starch
Study NCT04285073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting graft
Description: Implantation of e-PTFE Grafts inner surface-treated with paclitaxel as access for hemodialysis
Study NCT01235260 — intervention group
Intervention type: OTHER
Intervention: Becaplermin nonusers
Description: A cohort of becaplermin nonusers (ie, patients who are not treated with becaplermin but are similar in characteristics to patients in the becaplermin user cohort)
Study NCT01235260 — intervention group
Intervention type: DRUG
Intervention: Becaplermin users
Description: A cohort of becaplermin users (ie, patients with diabetes treated with becaplermin)
Study NCT01932905 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deep rTMS
Description: Patients undergoing of repetitive transcranial magnetic stimulation for treatment of central pain
Study NCT01932905 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: deep rTMS
Description: Patients undergoing of repetitive transcranial magnetic stimulation for treatment of central pain
Study NCT03814122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action-based cognitive remediation
Description: Action-Based Cognitive Remediation (ABCR) is a new program that was developed to address the challenges of transferring cognitive gains to improved quality of life and reduced disability. ABCR combines traditional cognitive training with an added behavioural component (e.g., role-plays, simulations of real world tasks) to foster learning through rehearsal and procedural memory which increases the likelihood of participants bridging cognitive strategies into real-world activities. ABCR also includes goal setting and behavioural activation procedures to stimulate transfer of in-session gains to everyday life changes.
Study NCT03814122 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Action-based cognitive remediation
Description: Action-Based Cognitive Remediation (ABCR) is a new program that was developed to address the challenges of transferring cognitive gains to improved quality of life and reduced disability. ABCR combines traditional cognitive training with an added behavioural component (e.g., role-plays, simulations of real world tasks) to foster learning through rehearsal and procedural memory which increases the likelihood of participants bridging cognitive strategies into real-world activities. ABCR also includes goal setting and behavioural activation procedures to stimulate transfer of in-session gains to everyday life changes.
Study NCT03814122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control Group
Description: Receive treatment-as-usual through regular early psychosis programming.
Study NCT02623218 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: An acupuncture needle is a device intended to pierce the skin in the practice of acupuncture. The device consists of a solid, stainless steel needle. The device may have a handle attached to the needle to facilitate the delivery of acupuncture treatment.
Study NCT02623218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: An acupuncture needle is a device intended to pierce the skin in the practice of acupuncture. The device consists of a solid, stainless steel needle. The device may have a handle attached to the needle to facilitate the delivery of acupuncture treatment.
Study NCT02623218 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Sham acupuncture will be performed at the same locations as verum acupuncture. Streitberger sham acupuncture needles look like real acupuncture needles, and appear as though the skin is being penetrated during the insertion technique, however they do not pierce the skin.
Study NCT03366428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a
Description: DS-8201a is supplied as a lyophilized powder which is reconstituted for infusion
Study NCT03410030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: combination therapy
Study NCT03410030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel protein-bound
Description: combination therapy
Study NCT03410030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: combination therapy
Study NCT03410030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: combination therapy
Study NCT05206162 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: theta burst stimulation
Description: TBS over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered.
Study NCT05206162 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: theta burst stimulation
Description: TBS over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered.
Study NCT02050321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acitretin
Description: A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
Study NCT02050321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
Study NCT03050866 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cabazitaxel
Description: 25mg/m2 q3w
Study NCT03050866 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Antihistamine
Description: As intravenous premedication (dexchlorpheniramine 5 mg, diphenhydramine 25 mg, or equivalent)
Study NCT03050866 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Corticosteroid
Description: As intravenous premedication (dexamethasone 8 mg or equivalent)
Study NCT03050866 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: H2 antagonist
Description: As intravenous premedication (ranitidine or equivalent)
Study NCT03050866 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Antiemetic
Description: Antiemetic prophylaxis is recommended and can be given orally or intravenously if necessary
Study NCT00096460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide and Rituximab
Description: Prior to undergoing HSCT, all patients will receive Cyclophosphamide 4 gm/m2 with Rituximab 375 mg/m2 x 2 doses and G-CSF support.
Study NCT00096460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Autologous HSCT patients will receive 10 mcg/kg/day and allogeneic HSCT patients will receive 5 mcg/kg/day subcutaneous (SQ) or intravenous (IV) starting 2 days after the initiation of Cyclophosphamide.
Study NCT00096460 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy or Radiation therapy
Description: Chemotherapy - BCNU 15 mg/kg IV x 1 dose to be administered over 2 hours on Day -6 pre-HSCT. VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4.~Radiation - administered at a rate of \< 20 cGy/min in one of the following doses; 120 cGy/fraction are administered at no less than 4-hour intervals three times/day or 2 times/day for a total of 10 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5), or doses of 150 cGy/fraction twice daily for a total of 8 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5). VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4 pre-HSCT.~Cyclophosphamide 100 mg/kg IV x 1 dose to be administered over 2 hours on Day -2 pre-HSCT. G-CSF 5 mcg/kg SQ or IV to start on Day +5 post-HSCT and continue until ANC > 500/mm3 x 3 days.
Study NCT00096460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-myeloablative Conditioning regimen
Description: Fludarabine 30 mg/m2 IV x 3 doses total to be administered daily over 30 minutes on Days -6, -5 and -4 pre-HSCT. Cyclophosphamide 750 mg/m IV x 3 doses total to be administered daily over 1 hour on Days -6, -5 and -4 pre-HSCT. Administer cyclophosphamide approximately 4 hours after start of fludarabine infusion. Rituximab 375 mg/m2 IV x 4 doses total to be administered on Days -13 and -6 pre HSCT and Days +1 and +8 post HSCT.
Study NCT00096460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic transplant
Description: Infusion of G-CSF mobilized allogeneic hematopoietic stem cells
Study NCT00096460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous transplant
Description: Infusion of G-CSF mobilized autologous hematopoietic stem cells
Study NCT00096460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab maintenance therapy
Description: Patients must have sufficiently recovered from autologous HSCT in order to receive rituximab maintenance therapy as specified below:~Dose #1: Day +42 post-autologous HSCT Dose #2: Day +49 post-autologous HSCT Dose #3: Day +56 post-autologous HSCT Dose #4: Day +63 post-autologous HSCT
Study NCT00096460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GVHD Prophylaxis
Description: Tacrolimus 0.09 mg/kg/day PO, based on body weight formulas will start on Day -2 and continue until Day +90 post-HSCT. Tacrolimus (or cyclosporine, if applicable) will be given orally in a twice-daily divided dose. Methotrexate 5 mg/m2 Intravenous Pyelogram (IVP) will be administered on Days +1, +3 and +6 post-HSCT.
Study NCT05183451 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: En- masse retraction and LLLT
Description: Retraction will start on a 0.019x0.025 Stainless steel wire using NiTi closed coils (force applied will be 200 g per side) extending between the crimpable hooks and the TADs. LLLT will be applied on days 0,3,7,14 from extraction then repeated biweekly till the end of retraction.
Study NCT05183451 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: En- masse retraction without LLLT
Description: Retraction will start on a 0.019x0.025 Stainless steel wire using NiTi closed coils (force applied will be 200 g per side) extending between the crimpable hooks and the TADs.
Study NCT02579005 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patients with a living donor
Description: The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n. The dose of external radiation will be 15 Gy divided in 3 fractions, from Day -3. Cyclophosphamide, 250 mg/m2 will be given on Day -2. Donors will receive 5 daily doses of GCSF, 10 µg/kg, by subcutaneous injection from Day -4. PBMC will be collected through apheresis on Day 0. A dose of 5 x 10exp7 CD3 cells/kg will be administered. The infused volume will be adjusted to contain this T cell dose.
Study NCT02579005 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patients with a UCB donor
Description: The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n. The UCB unit should have at least 4 of 6 HLA compatibility and at least 3 x 10exp6 TNC per kg patient weight. The dose of external radiation will be 15 Gy, divided in 3 fractions, starting on Day -3. Cyclophosphamide, 250 mg/m2 intravenously, will be given on Day -2.
Study NCT00957762 — intervention group
Intervention type: OTHER
Intervention: Body composition
Description: Day 1 testing will incorporate underwater weighing, Bod Pod, DXA, BIA and anthropometrics. Day 2 will include RMR, MRI, and testing at GCRC
Study NCT02225457 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypercaloric diet
Description: Hypercaloric diet will be designed to provide 50% excess in calories compared to daily requirements. It will consist in a snack type, high fat and high carbohydrates diet.
Study NCT02225457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypercaloric diet
Description: Hypercaloric diet will be designed to provide 50% excess in calories compared to daily requirements. It will consist in a snack type, high fat and high carbohydrates diet.
Study NCT02225457 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: polyphenols
Description: Administration of polyphenols will consist in the administration of 1 gram (5x200 mg) of the compound bid during the entire overfeeding period.
Study NCT02225457 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: placebo (for polyphenols)
Description: Placebo will consist in the administration of a number of placebo pills matching that of polyphenols, in a similar way (bid) for the duration of the overfeeding experiment.
Study NCT03228043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CAPEOX
Description: CAPEOX adjuvant chemotherapy for resectable colorectal
Study NCT03606460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab Dose 1
Description: 300 mg infusion administered to ocrelizumab-naive participants per approved protocol (over approximately 2.5 hours or longer) as per standard of care followed by a second 300 mg shorter infusion over approximately 1.5 hours.
Study NCT03606460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab Dose 2 and Dose 3
Description: 600 mg infusion of ocrelizumab administered at a shorter rate (i.e. over the course of approximately 2 hours) at Week 24 and at Week 48
Study NCT00614276 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus Group
Description: To evaluate a multimedia intervention program for women with cancer-related sexual dysfunction.
Study NCT00614276 — intervention group
Intervention type: BEHAVIORAL
Intervention: TENDRILS
Description: Tendrils: A Sexual Renewal Program for Women Surviving Cancer - a website designed to give women information about sexual problems related to cancer and its treatment, and the website suggests ways to overcome those problems.
Study NCT00614276 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: The questionnaires ask about your background (such as age, education, relationships), your cancer diagnosis and treatment, and the quality of your life in terms of your health, your general emotions, and your sexual function. The questionnaires take about 30-45 minutes to complete.
Study NCT00614276 — intervention group
Intervention type: BEHAVIORAL
Intervention: Sexual Counseling Sessions
Description: Attend 3 sexual counseling sessions at M. D. Anderson.
Study NCT04507698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Exercise Intervention
Description: INTense Exercise foR surVivAL among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL - MCRPC), randomised to either the supervised exercise arm or the self-directed exercise arm.
Study NCT04316962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex cancer rehabilitation
Description: The program is conducted as group rehabilitation, organized by four hour weekly over 12 weeks (approximately 50 hours) with 8-10 participants in each group over three years. The program is located in Askøy Municipality's 'Health Central' and conducted by a multidisciplinary team.~The content of the program is based on prior research and clinical experience, consisting of five elements:~1. Individual goal-setting~2. Physical activity (2 hours/week) focusing on balance/coordination, cardio and strength.~3. Psychoeducation: Five teaching sessions and discussions focusing on physical activity, fatigue and late-effects, nutrition, coping, social support and work/studies. In addition, two sessions (first and last) will also include next of kin.~4. Individual follow-up: Mandatory session at the start and end of the program, otherwise based on individual request and need.~5. Peer support.